Navigation Links
Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
Date:5/23/2013

0 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. Huntington's disease is a hereditary neurodegenerative disorder that leads to movement, cognition, and behavioral abnormalities and premature death. Cognitive dysfunction is responsible for substantial disability in these diseases and is not improved by current medications. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders. In addition to potential benefits on cognition, OMS824 could also improve psychiatric manifestations, such as the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of schizophrenia.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statemen
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
2. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
3. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
4. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
5. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
6. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
7. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
8. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
9. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
10. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
11. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Varian Medical Systems (NYSE: VAR) today broke ground on new ... City manufacturing facility and allow for the consolidation ... to ultimately create 1,000 new full time jobs in ... " Utah is home to hardworking people ... be credited with Varian,s success in the manufacturing of our ...
(Date:8/27/2014)... ANGELES , Aug. 27, 2014   Los ... now offers AcceleDent® Aura to patients who want to ... orthodontic care available at the OrthoSpaceship, all patients have ... better-looking teeth. This system can be used by most ... their rate of progress by using the AcceleDent® Aura ...
(Date:8/27/2014)... , August 27, 2014 ... Equipment Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental ... published by MarketsandMarkets, the global Dental Equipment Market is ... $5,416.3 million in 2014, growing at a CAGR ... Browse 95 market data tables and 61 figures ...
Breaking Medicine Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 4Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3
... Nov. 23 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) ... U.S. Food and Drug Administration (FDA) on January 20, 2010 ... Application (NDA) for Intermezzo ® (zolpidem tartrate ... by Transcept on October 28, 2009, indicated that the FDA ...
... , ORANGE COUNTY, Calif., Nov. 23 ... a leading developer, manufacturer, and marketer of products that ... that Allan Harris, Beckman Coulter,s vice president of strategy, ... Wednesday, December 2, 2009 at 12:00 p.m. (ET). , ...
Cached Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2
(Date:8/27/2014)... Aeroflow Healthcare has announced it ... of a strategic expansion of its durable medical ... ownership of new businesses through additional resources and ... , Last week, the company announced that it ... increase service in the High Point/Greensboro/Winston-Salem area. This ...
(Date:8/27/2014)... A St. Louis law firm that represents ... that the C.R. Bard multidistrict litigation (MDL), an MDL ... lawsuits, recently filed a new pretrial order (PTO) on ... discovery process, and more specifically to the management of ... & Lowe is a law firm practicing defective medical ...
(Date:8/27/2014)... New York (PRWEB) August 28, 2014 ... Market Research "Surgical Navigation Systems Market (Neurosurgical Navigation Systems, ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... valued at USD 218.5 million in 2013 and is ... 2014 to 2020, to reach an estimated value of ...
(Date:8/27/2014)... August 28, 2014 Recently, BambooIndustry.com, an innovative ... has announced that new bamboo panels are now ... providing deep discounts for clients worldwide. All people that place ... discounted rate, from 10 to 30 percent off. , ... new panels. “At the moment, all our new and old ...
(Date:8/27/2014)... August 28, 2014 DiaSorin has announced ... of 1,25 Dihydroxyvitamin D,” will feature guest speaker Dr. ... George Institute for Health and Healing Integrative Medicine. Dr. ... Penny George Institute for Health and Healing and as ... Care, Minneapolis, Minnesota. He also serves as a co-editor ...
Breaking Medicine News(10 mins):Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2Health News:Carey Danis & Lowe Reports On New Court Order in C.R. Bard Transvaginal Mesh MDL 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Health News:BambooIndustry.com: Cheap Bamboo Panels for Clients Worldwide Offered Online 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 3
... 2008 at 11:00 AM ET, LIVINGSTON, N.J., May ... recognized leader in advanced,injection technologies, today announced that the ... ended March 31, 2008 on Thursday,May 15, 2008., ... 2008, beginning,at 11:00 AM Eastern time, and invites all ...
... funding to PBTF Institute at Duke accelerates search for ... ... The Pediatric Brain,Tumor Foundation (PBTF) is giving an additional $6 million ... to $12 million., To view the Multimedia News Release, go ...
... for prehypertensive people in morning use, researchers report , , ... can control prehypertension, but only if it is taken ... taken every morning didn,t lower the blood pressure of ... C. Hermida reported Wednesday at the American Society of ...
... Del., May 14 AstraZeneca (NYSE:,AZN) today announced ... has,approved SEROQUEL(R) (quetiapine fumarate tablets) for the maintenance,treatment ... therapy to,lithium or divalproex. SEROQUEL is approved by ... also the only single agent approved by the ...
... AMRN ) today announced a private placement ... ("ADSs") with several new,institutional and accredited investors, and ... $60 million funded over two equal tranches., ... agreements for,gross proceeds of up to $56 million, ...
... Mass., and SYDNEY, Australia, May 14 /PRNewswire-FirstCall/,-- HeartWare Limited ... an investor presentation at the Seventh Annual JMP Securities ... Wednesday, May 21, 2008. The,conference is being held at ... webcast of the Company,s presentation at the conference will ...
Cached Medicine News:Health News:Milestone Scientific to Announce First Quarter 2008 Results on Thursday, May 15, 2008 2Health News:Video: Pediatric Brain Tumor Foundation Gives $6 Million Grant to Duke 2Health News:Aspirin at Bedtime Lowers Blood Pressure 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 3Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 4Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 5Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 6Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 7Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 8Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 9Health News:Amarin Announces Private Placement for up to $60 Million 2Health News:Amarin Announces Private Placement for up to $60 Million 3Health News:Amarin Announces Private Placement for up to $60 Million 4Health News:Amarin Announces Private Placement for up to $60 Million 5Health News:HeartWare to Present at Seventh Annual JMP Securities Research Conference 2
... a user friendly computerized medical record system ... and productivity of the practice as well ... documentation. It provides clinical templates for commonly ... It also contains an exhaustive database to ...
... GE Medical Systems Information ... see for yourself how ... Physician Office - Practice ... Manager) can simplify your ...
... 2V slit lamp is ... lamp that is designed ... tower and has standard ... Revolutionary design provides increased ...
... ReSeeVit CR-DGi Retinal Camera System is an ... retinal segment images for documentation, diagnosis and ... CR-DGi retinal camera for optimal performance. We ... designed for anterior segment images. ReSeeVit is ...
Medicine Products: